Moderna (MRNA) Stock Price & Analysis
MRNA Stock Chart & Stats
- Day’s Range
- MXN 4,120.00 - MXN 4,200.00
- 52-Week Range
- MXN 414.00 - MXN 4,750.00
- Previous Close
- MXN 4,199.64
- Volume
- 179
- Average Volume (3M)
- 2,769
- Market Cap
- MXN 1.66T
- Enterprise Value
- MXN 24.02B
- Total Cash (Recent Filing)
- MXN 5.14B
- Total Debt (Recent Filing)
- MXN 1.29B
- Price to Earnings (P/E)
- ―
- Beta
- 1.15
- Next Earnings
- Nov 06, 2026 (Est.)
- EPS Estimate
- -20.59
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Financial Flexibility
Manageable leverage and substantial liquidity give Moderna room to fund research, launches, and operating needs while absorbing volatility. This financial flexibility can support strategic investment in oncology and respiratory products without immediate reliance on additional external capital.
Respiratory Portfolio Expansion
Broader approvals and commercial availability expand Moderna’s addressable respiratory market beyond its original COVID franchise. A wider portfolio across geographies can support recurring seasonal revenue and reduce dependence on a single product as vaccination markets mature.
Cost Efficiency
Lower manufacturing and operating expenses show progress aligning the cost base with the post-pandemic revenue environment. If maintained, this discipline can extend the company’s cash runway, improve operating leverage, and preserve funding for priority pipeline programs.
Bears Say
Deep Profitability Pressure
Severely negative margins indicate that current commercial revenue does not yet cover the cost structure required to operate and develop the pipeline. Continued losses could erode equity, constrain investment capacity, and make a durable earnings recovery dependent on successful launches.
Persistent Cash Burn
Ongoing cash outflows mean Moderna is not currently self-funding its operations or development investments, despite its liquidity cushion. Persistent burn reduces financial flexibility over time and increases the importance of expense control, revenue recovery, and successful pipeline execution.
COVID Revenue Exposure
The outlook remains exposed to declining COVID vaccination demand while several expected products contribute no 2026 revenue under current guidance. This creates a difficult transition period in which newer respiratory and pipeline programs must scale before they can offset the mature core franchise.
Moderna News
Moderna’s Next‑Gen Pediatric Covid Shot Enters Key Phase 2 Test: What Investors Should Watch
Moderna ($MRNA) announced an update on their ongoing clinical study. The study “A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in
Moderna’s Next Flu Move: New Pediatric mRNA-1010 Trial Targets Long-Term Vaccine Growth
Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. has launched a new Phase 1 study titled “A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity,
MRNA FAQ
What was Moderna’s price range in the past 12 months?
What is Moderna’s market cap?
When is Moderna’s upcoming earnings report date?
How were Moderna’s earnings last quarter?
Is Moderna overvalued?
Does Moderna pay dividends?
What is Moderna’s EPS estimate?
How many shares outstanding does Moderna have?
What happened to Moderna’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Moderna?
What is the TipRanks Smart Score and how is it calculated?
Moderna Stock Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel
- Employees
- 4,700
- Website
- www.modernatx.com
- Address
- 325 Binney Street, Cambridge, MA, 02142, US
Moderna (MRNA) Earnings & Revenues
MRNA Company Deck
MRNA Earnings Call
Earnings Call SentimentPositive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.
View all MX:MRNA earnings summariesMRNA Net sales Breakdown
- 61.68% U.S.
- 2.73% Europe
- 35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 6 | 0 |
| Technical Analysis | 4 | 6 | 0 |
| Moving Averages | 12 | 0 | 0 |